TACE Combined With Iodine [131I] Metuximab Infusion May Improve Overall Survival in Unresectable HCC

For the treatment of patients with unresectable hepatocellular carcinoma (HCC), the combination of transcatheter arterial chemoembolization (TACE) with iodine [131I] metuximab infusion may improve local efficacy and overall survival when compared with TACE alone, according to an article in Clinics and Research in Hepatology and Gastroenterology.

A literature search of PubMed, Cochrane Library, Embase, Web of Science, China Biology Medicine, China Science and Technology Journal Database, Wan Fang Data, and Chinese knowledge resource integrated databases for controlled clinical trials comparing the combination TACE and iodine [131I] metuximab infusion with TACE-alone for the treatment of patients with HCC before February 1, 2016 was undertaken. A meta-analysis was done using the Jadad system evaluation method for research quality and RevMan 5.0 software.

The literature search produced 10 studies with a total of 1302 patients. Meta-analysis showed  the combination treatment was more effective than TACE alone. Six-month survival (odds ratio [OR] = 2.05, 95% confidence interval [CI]: 1.41-2.98, P = 0.0002), 1-year survival (OR = 1.90, 95% CI: 1.41-2.55, P < 0.00001), and the total response rate (OR = 2.91, 95% CI: 2.08-4.07, P < 0.00001) were improved with the combination treatment.

Adverse reactions were reported in 9 studies and included poor appetite, nausea, vomiting, and abdominal discomfort, with fever, chills, and bone marrow suppression being more common in patients who were treated with the combination of TACE and iodine [131I] metuximab infusion. Abnormal liver function was not different between the 2 treatment groups and there were no reported serious complication or deaths related to either treatment.

The researchers concluded that for the treatment of patients with unresectable HCC, the combination of TACE with iodine [131I] metuximab infusion may improve local efficacy and overall survival when compared with TACE alone.

 

--Kelsey Moroz

 

Reference

Fan W, Wu Y, Lu M, et al. A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2018. pii: S2210-7401(18)30188-8. doi: 10.1016/j.clinre.2018.09.006. [Epub ahead of print].